Allosteric modulators of GPCRs often provide higher selectivity for individual GPCR subtypes than has been achieved with traditional orthosteric-site ligands. Allosteric ligands can provide novel ...

Positive and negative allosteric modulators (PAMs and NAMs) have now been identified for members of each major subfamily of G protein-coupled receptors (GPCRs). Multiple allosteric modulators have ...

allosteric modulation, and advancement of GPCRs from preclinical to clinical studies, particularly with small molecule drug candidates. Guido Zaman, Ph.D., who heads assay development and ...

In addition, Addex is applying its proprietary discovery platform to identify highly selective and potent allosteric modulators of a number of both GPCR and non-GPCR targets that are implicated in ...

Evotec's insights into GPCRs and waveRAPID technology reveal new opportunities in drug discovery, focusing on orphan ...

Geneva, Switzerland, 12 November 2010 – Allosteric modulation company Addex Pharmaceuticals ... to expand our discovery technology beyond GPCRs, like glutamate receptors, to cover other types ...

About GABAB Activation with PAM: Activation of gamma-aminobutyric acid subtype B (GABAB) receptor, a Family C class of GPCR ... of novel small molecule allosteric modulators for neurological ...

Domain Therapeutics has announced that it has entered into a multi-step collaboration with XOMA Corporation, a leader in the discovery and development of therapeutic antibodies. XOMA, a California ...

“While the challenges of this field are complex, targeting the GABAB receptor with positive allosteric modulators offers ... a Family C class of GPCR, is clinically and commercially validated.

Geneva, Switzerland, May 12, 2025-Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a ...